Financials ReShape Lifesciences Inc.
Equities
RSLS
US76090R2004
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1698 USD | -4.61% | +2.72% | -32.00% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 2.034 | 19.83 | 29.17 | 3.259 | 4.624 | 3.983 | - |
Enterprise Value (EV) 1 | 2.034 | 19.83 | 29.17 | 3.259 | 4.624 | 3.983 | 3.983 |
P/E ratio | -0.13 x | -1.14 x | -0.33 x | -0.06 x | -0.13 x | -0.38 x | -0.47 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | 1.76 x | 2.14 x | 0.29 x | 0.53 x | 0.4 x | 0.33 x |
EV / Revenue | - | 1.76 x | 2.14 x | 0.29 x | 0.53 x | 0.4 x | 0.33 x |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 7.08 | 112 | 356 | 484 | 18,518 | 23,457 | - |
Reference price 2 | 287.5 | 177.5 | 82.00 | 6.740 | 0.2497 | 0.1698 | 0.1698 |
Announcement Date | 4/30/20 | 3/10/21 | 3/28/22 | 4/17/23 | 4/1/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 11.3 | 13.6 | 11.24 | 8.678 | 9.994 | 11.99 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -12.46 | -27.75 | -46.35 | -15.38 | -6.71 | -5.818 |
Operating Margin | - | -110.25% | -204.04% | -412.38% | -177.26% | -67.14% | -48.51% |
Earnings before Tax (EBT) 1 | - | -21.81 | -62.04 | -46.59 | -11.34 | -6.654 | -5.762 |
Net income 1 | -74.21 | -21.63 | -61.93 | -46.21 | -11.39 | -6.654 | -5.762 |
Net margin | - | -191.43% | -455.39% | -411.16% | -131.22% | -66.58% | -48.04% |
EPS 2 | -2,146 | -156.0 | -250.0 | -108.9 | -1.910 | -0.4500 | -0.3600 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/30/20 | 3/10/21 | 3/28/22 | 4/17/23 | 4/1/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 3.708 | 3.142 | 2.44 | 2.892 | 2.798 | 3.11 | 2.287 | 2.254 | 2.155 | 1.982 | 2.104 | 2.209 | 2.508 | 3.173 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -14.98 | -6.805 | -8.4 | -9.376 | -11.93 | -16.65 | -5.631 | -3.976 | -3.88 | -1.895 | -2.177 | -1.85 | -1.526 | -1.156 |
Operating Margin | -404.1% | -216.58% | -344.26% | -324.2% | -426.23% | -535.34% | -246.22% | -176.4% | -180.05% | -95.61% | -103.47% | -83.75% | -60.85% | -36.43% |
Earnings before Tax (EBT) 1 | -17.73 | -35.59 | -8.372 | -9.567 | -12.17 | -16.48 | -2.648 | -3.489 | -3.531 | -1.667 | -2.163 | -1.836 | -1.512 | -1.142 |
Net income 1 | -17.7 | -35.46 | -8.215 | -9.576 | -11.81 | -16.61 | -2.662 | -3.493 | -3.534 | -1.698 | -2.163 | -1.836 | -1.512 | -1.142 |
Net margin | -477.32% | -1,128.52% | -336.68% | -331.12% | -422.12% | -534.15% | -116.4% | -154.97% | -163.99% | -85.67% | -102.8% | -83.11% | -60.29% | -35.99% |
EPS 2 | -74.00 | -124.5 | -22.00 | -25.00 | -26.00 | -35.90 | -1.560 | -1.080 | -1.020 | - | -0.1600 | -0.1200 | -0.1000 | -0.0700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/11/21 | 3/28/22 | 5/23/22 | 8/15/22 | 11/14/22 | 4/17/23 | 5/15/23 | 8/7/23 | 11/8/23 | 4/1/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | 0.35 | - | - | - | - |
Capex / Sales | - | - | 2.59% | - | - | - | - |
Announcement Date | 4/30/20 | 3/10/21 | 3/28/22 | 4/17/23 | 4/1/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.00% | 3.98M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- RSLS Stock
- Financials ReShape Lifesciences Inc.